BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 8433875)

  • 1. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ADA human gene therapy clinical protocol.
    Hum Gene Ther; 1990; 1(3):327-62. PubMed ID: 2081198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
    Onodera M; Ariga T; Kawamura N; Kobayashi I; Ohtsu M; Yamada M; Tame A; Furuta H; Okano M; Matsumoto S; Kotani H; McGarrity GJ; Blaese RM; Sakiyama Y
    Blood; 1998 Jan; 91(1):30-6. PubMed ID: 9414266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
    J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow gene therapy for adenosine deaminase deficiency.
    Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
    Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS; Chaffee S; Sorensen RU
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte gene therapy.
    Culver KW; Anderson WF; Blaese RM
    Hum Gene Ther; 1991; 2(2):107-9. PubMed ID: 1911929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
    N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
    Blaese RM; Culver KW; Miller AD; Carter CS; Fleisher T; Clerici M; Shearer G; Chang L; Chiang Y; Tolstoshev P; Greenblatt JJ; Rosenberg SA; Klein H; Berger M; Mullen CA; Ramsey WJ; Muul L; Morgan RA; Anderson WF
    Science; 1995 Oct; 270(5235):475-80. PubMed ID: 7570001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy.
    Misaki Y; Ezaki I; Ariga T; Kawamura N; Sakiyama Y; Yamamoto K
    Mol Ther; 2001 Jan; 3(1):24-7. PubMed ID: 11162307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS
    Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
    Ramsey WJ; Mullen CA; Blaese RM
    Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y
    Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
    Hershfield MS
    Hum Mutat; 1995; 5(2):107-12. PubMed ID: 7749407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.